These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 31017794)
21. A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, part I: a comparative analysis by thermally stimulated depolarization current and differential scanning calorimetry. Shmeis RA; Wang Z; Krill SL Pharm Res; 2004 Nov; 21(11):2025-30. PubMed ID: 15587924 [TBL] [Abstract][Full Text] [Related]
22. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques. Meng F; Gala U; Chauhan H Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292 [TBL] [Abstract][Full Text] [Related]
23. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects. Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226 [TBL] [Abstract][Full Text] [Related]
24. Early drug development predictions of glass-forming ability and physical stability of drugs. Mahlin D; Bergström CA Eur J Pharm Sci; 2013 May; 49(2):323-32. PubMed ID: 23557841 [TBL] [Abstract][Full Text] [Related]
25. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228 [TBL] [Abstract][Full Text] [Related]
26. Correlating thermodynamic and kinetic parameters with amorphous stability. Graeser KA; Patterson JE; Zeitler JA; Gordon KC; Rades T Eur J Pharm Sci; 2009 Jun; 37(3-4):492-8. PubMed ID: 19394421 [TBL] [Abstract][Full Text] [Related]
27. An improved kinetics approach to describe the physical stability of amorphous solid dispersions. Yang J; Grey K; Doney J Int J Pharm; 2010 Jan; 384(1-2):24-31. PubMed ID: 19786081 [TBL] [Abstract][Full Text] [Related]
28. Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Vasanthavada M; Tong WQ; Joshi Y; Kislalioglu MS Pharm Res; 2004 Sep; 21(9):1598-606. PubMed ID: 15497685 [TBL] [Abstract][Full Text] [Related]
29. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651 [TBL] [Abstract][Full Text] [Related]
30. Crystallization Propensity of Amorphous Pharmaceuticals: Kinetics and Thermodynamics. Krishna Kumar NS; Suryanarayanan R Mol Pharm; 2022 Feb; 19(2):472-483. PubMed ID: 34979803 [TBL] [Abstract][Full Text] [Related]
31. Co-former selection for co-amorphous drug-amino acid formulations. Kasten G; Löbmann K; Grohganz H; Rades T Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980 [TBL] [Abstract][Full Text] [Related]
32. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Ghebremeskel AN; Vemavarapu C; Lodaya M Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443 [TBL] [Abstract][Full Text] [Related]
34. Thermodynamic behavior of glassy state of structurally related compounds. Kaushal AM; Bansal AK Eur J Pharm Biopharm; 2008 Aug; 69(3):1067-76. PubMed ID: 18420396 [TBL] [Abstract][Full Text] [Related]
35. Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion? Qian F; Huang J; Zhu Q; Haddadin R; Gawel J; Garmise R; Hussain M Int J Pharm; 2010 Aug; 395(1-2):232-5. PubMed ID: 20562003 [TBL] [Abstract][Full Text] [Related]
36. Molecular implications of drug-polymer solubility in understanding the destabilization of solid dispersions by milling. Yang Z; Nollenberger K; Albers J; Qi S Mol Pharm; 2014 Jul; 11(7):2453-65. PubMed ID: 24897345 [TBL] [Abstract][Full Text] [Related]
37. Physical stability of the amorphous anticholesterol agent (ezetimibe): the role of molecular mobility. Knapik J; Wojnarowska Z; Grzybowska K; Hawelek L; Sawicki W; Wlodarski K; Markowski J; Paluch M Mol Pharm; 2014 Nov; 11(11):4280-90. PubMed ID: 25310722 [TBL] [Abstract][Full Text] [Related]
38. Local mobility in amorphous pharmaceuticals--characterization and implications on stability. Bhattacharya S; Suryanarayanan R J Pharm Sci; 2009 Sep; 98(9):2935-53. PubMed ID: 19499564 [TBL] [Abstract][Full Text] [Related]
39. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds. Trasi NS; Baird JA; Kestur US; Taylor LS J Phys Chem B; 2014 Aug; 118(33):9974-82. PubMed ID: 25076138 [TBL] [Abstract][Full Text] [Related]